Cookies help us improve your website experience.
九月 09, 2019
China has now stepped into its “golden age” of biopharma; this year regulators approved the country’s first biosimilar product, HLX01. Developed by Shanghai Henlius Biotech, it will be used primarily for treatment of non-Hodgkin’s lymphoma<span>. Biologics are sensitive large molecules, so selecting the appropriate packaging and delivery system is critical. To this end, West Pharmaceutical Services, Inc. (“West”) recently held <em>China BioPharma Summit for Injectable Drug Packaging and Delivery Systems</em> in Suzhou. Over 200 persons attended.</span>